Brian Anderson- November 11, 2019, 8:02 AM EDTSHARE ON:
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Celyad (CYAD), with a price target of $43.00. The company’s shares closed last Monday at $8.88, close to its 52-week low of $8.10.
According to TipRanks.com, White is a 5-star analyst with an average return of 15.5% and a 51.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $51.50, representing a 452.6% upside. In a report released today, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.89 and a one-year low of $8.10. Currently, Celyad has an average volume of 32.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
Als we deze analist moeten geloven heeft het meer upside dan zowat alle biotech aandelen die hier populair zijn bij elkaar!!